Where Arcus Biosciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for Arcus Biosciences (NYSE:RCUS) in the last quarter. In the last 3 months, 9 analysts have offered 12-month price targets for Arcus Biosciences, with an average price target of $46.0, an increase of 35.29% from the previous average price target of $34.00.
September 12, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have provided bullish ratings for Arcus Biosciences, with an increased average price target, indicating positive sentiment.
The bullish ratings and increased price target from analysts indicate a positive sentiment towards Arcus Biosciences. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100